SELECTED WORK

Experience behind the advice.

These examples show my role in ophthalmic research, product development and company building—and what the evidence did and did not establish.

01 / OPTICS + ENGINEERING

From optical measurement to individualised laser treatment.

Early results are useful when their limitations guide the next study or design decision.

The question: How can the optical characteristics of an individual eye inform a more individualized laser treatment?
My contribution: With Maik Kaemmerer and Theo Seiler, I worked on early wavefront-guided LASIK research. Our 2001 clinical paper also identified my scientific consultancy with WaveLight.
Evidence and outcome: A published clinical study connected wavefront measurements with customized treatment. It reported promising results alongside incomplete correction of higher-order aberrations and a need for further controlled studies.

02 / RESEARCH + TRANSLATION

Translation includes engineering, clinical evidence and a workable route to use.

The question: How can a corneal treatment move from scientific development into practical delivery?
My contribution: I contributed to cross-linking research and founded IROC Innocross, working with scientific, engineering and clinical colleagues on the UV-X devices.
Evidence and outcome: In 2014, Avedro acquired business assets and licensed intellectual property from IROC Innocross, including the UV-X device line. This was an asset and licensing transaction.

03 / MEASUREMENT + DEVELOPMENT

A measurement becomes valuable when it can inform a clinical decision.

The question: How can ocular measurements support individualized intraocular-lens planning?
My contribution: I co-founded ClearSight Innovations in 2013 and led product development as CTO, alongside co-founder and CEO Ronan Byrne and the team.
Evidence and outcome: The Mirricon concept combined measurements of the cornea, crystalline lens and axial length with optical ray tracing. The contemporaneous presentation describes proof-of-concept work; it does not establish superior clinical outcomes.

04 / BIOLOGY + COMPANY BUILDING

Technology, evidence generation and commercialisation need to advance together.

The question: Can shaped donor corneal tissue create an additional approach to vision correction?
My contribution: I co-founded Allotex with David Muller and serve as CEO. The work connects corneal tissue technology, clinical evidence and commercial development.
Evidence and outcome: In January 2026, Allotex announced conditional FDA approval of an Investigational Device Exemption for a U.S. presbyopia study, following commercialization outside the United States. This authorizes clinical investigation, not U.S. commercial use.

Selected collaborative contributions. Historical findings and development milestones are not claims of approval for every intended use or market.